Terlipressin-induced Peripheral Ischemic Gangrene in a Diabetic Patient
Phulen Sarma1, Gaurav Muktesh1, Narender Dhaka1, Rakesh Ruhela1, Abhishek Mishra1, Rahul Singh1, Saroj K. Sinha1, Bikash Medhi1★, Rakesh Kochhar1★ Corresponding author
- 1Departments of Pharmacology and Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
CORRESPONDENCE
Bikash Medhi
Departments of Pharmacology and Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Received: 18-03-2017; Revised: 16-04-2017; Accepted: 09-08-2017.
Volume 8, Issue 3 · pp. 148–150 · PUBLISHED 2017 · DOI: 10.4103/jpp.JPP_42_17
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Terlipressin is used commonly in the management of hepatorenal syndrome and acute variceal bleeding. Like its parent compound vasopressin, it is also notorious for its ischemic complications. Terlipressin-induced ischemic complications can virtually affect any part of the body, but the incidence of serious complications is less than its parent compound vasopressin. Here, we report a case of terlipressin-induced peripheral ischemic gangrene in a diabetic male, which ultimately led to death of the patient.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Sarma, P., Muktesh, G., Dhaka, N., Ruhela, R., Mishra, A., Singh, R., Sinha, S. K., Medhi, B., & Kochhar, R. (2017). Terlipressin-induced Peripheral Ischemic Gangrene in a Diabetic Patient. Journal of Pharmacology and Pharmacotherapeutics, 8(3), 148–150. https://doi.org/10.4103/jpp.JPP_42_17